Core Viewpoint - The company has signed a licensing and commercialization agreement with STADA for the exclusive commercialization rights of BAT1806 (Tocilizumab) in various regions, which is expected to positively impact future performance [1] Group 1: Agreement Details - The agreement grants STADA the exclusive commercialization rights for BAT1806 in the EU, Switzerland, the UK, parts of Europe, the Middle East, North Africa, and the Commonwealth of Independent States [1] - The transaction includes an upfront payment of €8.5 million, milestone payments totaling up to €127 million, and a double-digit percentage revenue share from net sales [1] Group 2: Financial Impact - The agreement is anticipated to have a positive effect on the company's future performance following its activation [1]